CD200 in acute myeloid leukemia : marked upregulation in CEBPA biallelic mutated cases
González-Guerrero, L. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Castellet, Helena (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Martínez, Clara (Institut de Recerca Sant Pau)
González, Nuria (Institut de Recerca Sant Pau)
Guijarro, Francesca (Hospital Clínic i Provincial de Barcelona)
Lloveras, Natàlia (Hospital Universitari de Girona Doctor Josep Trueta)
Pratcorona, Marta (Institut de Recerca Sant Pau)
Gich, Ignasi (Institut de Recerca Sant Pau)
Berenguer-Molins, Pau (Institut Hospital del Mar d'Investigacions Mèdiques)
Perera-Bel, Júlia (Institut Hospital del Mar d'Investigacions Mèdiques)
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mascaró, Martí (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Sampol, Antonia (Hospital de Son Espases)
Garcia-Guiñón, Antoni (Hospital Universitari Arnau de Vilanova)
Vives Polo, Susana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Tormo, Mar (Universitat de València)
Arnan, Montserrat (Hospital Universitari de Bellvitge)
Villamor, Neus (Hospital Clínic i Provincial de Barcelona)
Nomdedéu, Josep (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2025
Abstract:	CD200 is a glycoprotein that binds with its receptor CD200R, providing immunosuppressive signals to T and NK cells. CD200 is expressed by normal stem cells and progenitors committed to B-lymphopoiesis and myeloid development. CD200 biological relevance in acute leukemias is only partially understood. The study included a consecutive series of four hundred thirty-one patients with acute myeloid leukemia (AML). Immunophenotype was established by multiparametric flow cytometry, and the genetic diagnosis was performed by PCR-based methods and a targeted resequencing method covering 42 genes. 66% of AML patients expressed CD200 being significantly associated with CD34 reactivity. The frequency of CD200 positivity was higher in cases with core-binding factor genetic lesions such as RUNX1-RUNX1T1 (81. 3%) fusions and CBFB-MHY11 (63. 2%) rearrangements and also with biallelic CEBPA mutations (100%). The molecular AML group with the lowest CD200 reactivity (19. 1%) corresponded to AML with NPM1 mutations. RNA seq showed no uniform pattern of infiltrating cells in CEBPA mutated AML. Deconvolution analysis may be used to assess the immunoregulatory mechanisms of AML. CD200 expression could help identify the more immature compartment and, combined with other markers, single out CEPA-mutated AML.
Grants:	Generalitat de Catalunya 2014-SGR-383 Instituto de Salud Carlos III PI20/00867 Generalitat de Catalunya 2017-SGR-999
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	CEBPA -NPM1 ; FLT3 ; Acute myeloid leukemia- RUNX1 ; CD200
Published in:	Diagnostic Pathology, Vol. 20 Núm. 1 (december 2025) , p. 56, ISSN 1746-1596

DOI: 10.1186/s13000-025-01655-w
PMID: 40307896

13 p, 2.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles